| Title: | Regular use of pharmaceutical opioids and subsequent risk of cancer: a prospective cohort study and Mendelian randomization analysis |
| Journal: | EClinicalMedicine |
| Published: | 11 Nov 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/41357337/ |
| DOI: | https://doi.org/10.1016/j.eclinm.2025.103439 |
Publication 18962
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Background: Opium consumption was classified as "carcinogenic to humans" by the International Agency for Research on Cancer (IARC). We investigated whether use of pharmaceutical opioids, derived from or synthesized to mimic opium, is associated with cancer risk using separate observational and genetic analyses.</p>
Methods: Observational analysis included 472,955 participants in the UK Biobank prospective cohort (2006-2022). Genetic analysis included 2-sample Mendelian Randomization (MR) analyses using data from 14 independent genome-wide-association-studies (N = 9931-357,292). Adjusted hazard ratios (a-HR) or odds ratios (ORs) associated with regular opioid use were assessed for six established opium-related cancers (lung, pancreatic, bladder, esophageal, oropharyngeal, and laryngeal) and seven non-opium-related cancers (prostate, breast, colon, endometrial, kidney, ovarian, and brain).</p>
Findings: In UK Biobank, regular opioid use was associated with increased risk of opium-related cancers among ever-smoking [a-HR = 1.33 (95% CI = 1.22-1.43)] and never-smoking participants [a-HR = 1.32 (1.10-1.59)], but not non-opium-related cancers [a-HR = 0.96 (0.91-1.02)]. Risk increased with opioid strength [a-HR = 1.30 (1.20-1.40) for weak opioids; a-HR = 1.86 (1.43-2.40) for strong opioids, p-trend < 0.0001] and duration of action [a-HR = 1.32 (1.22-1.42) for short-acting; a-HR = 1.65 (1.24-2.18) for long-acting opioids, p-trend < 0.0001]. Both observational and genetic analyses showed increased risks for most opium-related cancers, including lung [a-HR = 1.39 (1.27-1.53); MR-Odds Ratio (OR) = 1.17 (1.07-1.29)], pancreas [a-HR = 1.24 (1.01-1.52); MR-OR = 1.34 (1.11-1.62)], bladder [a-HR = 1.26 (1.02-1.56); MR-OR = 1.15 (1.03-1.29)], esophagus [a-HR = 1.18 (0.94-1.49); MR-OR = 1.24 (1.01-1.52)], and larynx [a-HR = 1.37 (0.85-2.20); MR-OR = 1.29 (1.04-1.61)]. Except for an inverse association with prostate cancer [a-HR = 0.83 (0.76-0.91); MR-OR = 0.99 (0.92-1.05)], associations were null for non-opium-related cancers.</p>
Interpretation: Regular use of pharmaceutical opioids was associated with elevated risk for cancers caused by opium, but not other cancers.</p>
Funding: US National Institutes of Health, French National Cancer Institute.</p>
29 Authors
- Mahdi Sheikh
- Allison Domingues
- Karine Alcala
- Ryan Langdon
- Daniela Mariosa
- Xiaoshuang Feng
- Peter Sarich
- Marianne F Weber
- Vivian Viallon
- Agnes Fournier
- Farin Kamangar
- Reza Malekzadeh
- Chris Gillette
- Mara Z Vitolins
- Meredith C B Adams
- Shama Virani
- Elmira Ebrahimi
- Tom Dudding
- Tessel E Galesloot
- Lambertus A Kiemeney
- Nathaniel Rothman
- Stella Koutros
- Jifang Zhou
- Sallie-Anne Pearson
- Marie-Odile Parat
- Paul Brennan
- Mattias Johansson
- George Davey Smith
- Hilary A Robbins
1 Application
| Application ID | Title |
|---|---|
| 80725 | Opioid cohort consortium (OPICO) to investigate the effects of opioid use on the risk of cancer incidence and mortality |
Enabling scientific discoveries that improve human health